Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889644 | 1.00 | GPR119 (0.40) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL29889647 | 0.92 | GPR119 (0.40) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL6052905 | 0.90 | KLK7 (0.38) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL27043967 | 0.90 | KLK7 (0.38) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL6052900 | 0.90 | KLK7 (0.38) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL4378972 | 0.90 | KLK7 (0.38) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL30064881 | 0.90 | KLK7 (0.38) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL30977295 | 0.89 | GPR119 (0.38) | GPR119KDM4EPKMKLK7STS | |
| SCHEMBL23043370 | 0.88 | RIPK1 (0.37) | GPR119MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL26694476 | 0.88 | RIPK1 (0.37) | GPR119MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228510-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-07-11 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228510-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GPR119 1290/4885KDM4E 3742/4885PKM 4599/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | GPR119 1237/4885KDM4E 3689/4885PKM 4596/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GPR119 1237/4885KDM4E 3689/4885PKM 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.